Longer mirdametinib treatment increased confirmed and deep responses as treatment-related adverse effects declined in neurofibromatosis type 1 tumors.
|Articles|March 2, 2011
- January 2011
- Volume 5
- Issue 1
Men With Prostate Cancer Should Exercise
Author(s)Marissa Murtaugh
Men with prostate cancer reduce the risk of death from all causes by 46% if they do moderate exercise, such as walking, for 90 minutes a week
Advertisement
Men with prostate cancer reduce the risk of death from all causes by 46% if they do moderate exercise, such as walking, for 90 minutes a week. Men who perform vigorous exercise for >3 hours each week lower their overall mortality risk by 49%, suggests a study published in the Journal of Clinical Oncology. In addition, they reduce their risk of death from prostate cancer by 61% compared with men who exercise <1 hour each week. Outcomes are best for men who exercised routinely before diagnosis and continue to do so.
Articles in this issue
over 15 years ago
Cancer in the Workplaceover 15 years ago
Developing Optimal Patient Medication InformationAdvertisement
Related to this article
The phase 3 4WARD trial is evaluating mavorixafor for reducing infection rates and raising neutrophil counts in patients with primary chronic neutropenia.
Age, geographic location, transportation barriers, and language and communication barriers may limit patient opportunities to participate in research.
Phase 2 Co-PSMA data showed higher lesion detection with 64Cu-SAR-bisPSMA vs 68Ga-PSMA-11 in biochemical recurrence after prostatectomy.
Retrospective data tie longer survival with niraparib maintenance to homologous recombination deficiency after complete primary debulking.
Experts weigh genomic testing, treatment intensification, and radioligand sequencing in advanced prostate cancer care.
Exploratory BEHOLD-1 data show responses to mocertatug rezetecan in platinum-resistant ovarian cancer across B7-H4 expression levels.
Updated BEHOLD-1 data show mocertatug rezetecan at its selected dose produced lasting responses in platinum-resistant ovarian cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Durvalumab Plus Enfortumab Vedotin for Cisplatin-Ineligible MIBC
2
Dr Gleave on Selecting Patients for Perioperative Therapy in High-Risk Prostate Cancer
3
Dr Calais on Individualizing PSMA-Targeted Therapy Sequencing in Prostate Cancer
4
CHMP Recommends Approval of Belzutifan Plus Lenvatinib for Advanced ccRCC After PD-(L)1 Inhibition
5